Filtered By:
Procedure: Liver Transplant

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 197 results found since Jan 2013.

Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
CONCLUSIONS: Our data suggest that LC confers protection against intracranial atherosclerosis, and that thrombocytopenia may be involved in this protection. High CAC score could serve as a potential surrogate for cervicocerebral vascular screening in asymptomatic cirrhotics.PMID:34637612 | DOI:10.3350/cmh.2021.0202
Source: Clinical and molecular hepatology - October 12, 2021 Category: Gastroenterology Authors: Jihyun An Hyung Don Kim Seon-Ok Kim Ha Il Kim Gi-Won Song Han Chu Lee Ju Hyun Shim Source Type: research

Complications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation
ConclusionThere was no statistical significance for those within or out side the Milan criteria or UCSF criteria and its impact on the occurrence of graft rejection, sepsis, vascular complications, death, HCC recurrence and biliary complications post-transplant.
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Major Thromboembolic Complications in Liver Transplantation: The Role of Rotational Thromboelastometry and Cryoprecipitate Transfusion
Background. Although hemorrhage is a major concern during liver transplantation (LT), the risk for thromboembolism is well recognized. Implementation of rotational thromboelastometry (ROTEM) has been associated with the increased use of cryoprecipitate; however, the role of ROTEM-guided transfusion strategy and cryoprecipitate administration in the development of major thromboembolic complications (MTCs) has never been documented. Methods. We conducted a study on patients undergoing LT before and after the implementation of ROTEM. We defined MTC as intracardiac thrombus, pulmonary embolism, hepatic artery thromb...
Source: Transplantation - July 28, 2021 Category: Transplant Surgery Tags: Original Clinical Science—Liver Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ROTEM Testing for Direct Oral Anticoagulants
This article reviews the use of ROTEM in the setting of DOACs therapy, focusing on DOACs-associated bleeding and the use of this VHA for the management of reversal strategies for DOACs-associated anticoagulation. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Seminars in Thrombosis and Hemostasis - June 15, 2021 Category: Hematology Authors: Korpallov á, Barbora Samo š, Matej Bolek, Tom áš K ühnelová, Linda Škorňová, Ingrid Kubisz, Peter Sta ško, Ján Mok áň, Marián Tags: Review Article Source Type: research

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report
ConclusionsSince information is scarce regarding oncological treatment of patients following organ transplantation, data about their oncological treatment is essential. To our knowledge, this is the first case report to describe the successful chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a posttransplant patient with metastatic colorectal cancer.
Source: Journal of Medical Case Reports - March 20, 2021 Category: General Medicine Source Type: research

Predicting Post –Liver Transplant Outcomes—Rise of the Machines or a Foggy Crystal Ball?
ALTHOUGH LIVER transplantation (LT) provides a life-saving therapy to thousands of patients per year, many more die while awaiting transplantation resulting from critical organ shortages. Due to these shortages, patient selection is of paramount importance. Liver transplant programs strive to select recipients with high expected gains in life expectancy and low risks of complications. Major adverse cardiovascular events (MACE), such as myocardial infarction, heart failure, and stroke, may occur in approximately 23% of LT recipients within six months of transplantation.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 12, 2021 Category: Anesthesiology Authors: Matthew W. Vanneman, Vikram Fielding-Singh, Nima Aghaeepour Tags: Editorial Source Type: research

Predicting post-liver transplant outcomes —rise of the machines or a foggy crystal ball?
Although liver transplantation (LT) provides a life-saving therapy to thousands of patients per year, many more die while awaiting transplantation due to critical organ shortages. Due to these shortages, patient selection is of paramount importance. Liver transplant programs strive to select recipients with high expected gains in life expectancy and low risks of complications. Major adverse cardiovascular events (MACE), such as myocardial infarction, heart failure, and stroke, may occur in approximately 23% of LT recipients within 6 months of transplantation.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 12, 2021 Category: Anesthesiology Authors: Matthew W. Vanneman, Vikram Fielding-Singh, Nima Aghaeepour Tags: Editorial Source Type: research

Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury
Biomed Pharmacother. 2021 Feb 27;138:111441. doi: 10.1016/j.biopha.2021.111441. Online ahead of print.ABSTRACTMetabolic syndrome (MetS) is a complex, multifactorial disease which lead to an increased risk of cardiovascular disease, type 2 diabetes, and stroke. However, selective, and potent drugs for the treatment of MetS are still lacking. Previous studies have found that Akebia saponin D (ASD) has beneficial effects on metabolic diseases such as obesity, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). Therefore, our study was designed to determine the effect and mechanism of action of ASD against MetS in ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 2, 2021 Category: Drugs & Pharmacology Authors: Song Yang Ting Hu He Liu Ya-Li Lv Wen Zhang Han Li Lingling Xuan Li-Li Gong Li-Hong Liu Source Type: research

Cardiac surgery outcomes in patients with antecedent kidney, liver, and pancreas transplantation: a meta-analysis.
Authors: Bacusca AE, Enache M, Tarus A, Litcanu CI, Burlacu A, Tinica G Abstract Cardiovascular events are among the most common causes of late death in the transplant recipient (Tx) population. Moreover, major cardiac surgical procedures are more challenging and risky due to immunosuppression and the potential impact on the transplanted organ's functional capacity. We aimed to assess open cardiac surgery safety in abdominal solid organ transplant recipients, comparing the postoperative outcomes with those of nontransplant (N-Tx) patients. Electronic databases of PubMed, EMBASE, and SCOPUS were searched. The endpoi...
Source: Reviews in Cardiovascular Medicine - January 5, 2021 Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research